产品名称
3-羟基邻氨基苯甲酸, 97%
Quality Level
assay
97%
form
solid
reaction suitability
reaction type: solution phase peptide synthesis
mp
240 °C (dec.) (lit.)
application(s)
peptide synthesis
SMILES string
Nc1c(O)cccc1C(O)=O
InChI
1S/C7H7NO3/c8-6-4(7(10)11)2-1-3-5(6)9/h1-3,9H,8H2,(H,10,11)
InChI key
WJXSWCUQABXPFS-UHFFFAOYSA-N
General description
3-羟基邻氨基苯甲酸是一种氨基苯甲酸，通常用作各种化学反应的中间体。
Application
<ul>
<li><strong>直接抑制酶以减轻喹啉酸的形成：</strong>用于在色氨酸分解代谢的犬尿氨酸途径中合成 2-氨基-3-羧基粘康酸半醛 (ACMS)（Sanz 等人，2022 年）。</li>
</ul>
<li><strong>直接抑制酶以减轻喹啉酸的形成：</strong>用于在色氨酸分解代谢的犬尿氨酸途径中合成 2-氨基-3-羧基粘康酸半醛 (ACMS)（Sanz 等人，2022 年）。</li>
</ul>
signalword
Warning
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
Guifang Gan et al.
Cell death discovery, 7(1), 173-173 (2021-07-08)
Sorafenib is the FDA-approved first-line target drug for HCC patients. However, sorafenib only confers 3-5 months of survival benefit with <30% of HCC patients. Thus, it is necessary to develop a sensitizer for hepatocellular carcinoma (HCC) to sorafenib. Here, we
NO scavenging by 3-hydroxyanthranilic acid and 3-hydroxykynurenine: N-nitrosation leads via oxadiazoles to o-quinone diazides
C Backhaus, et al.
Nitric Oxide, 19, 237-244 (2008)
E R Werner et al.
Biological chemistry Hoppe-Seyler, 366(1), 99-102 (1985-01-01)
3-Hydroxyanthranilic acid was identified in lymphocyte cultures during allogeneic stimulation. The metabolite and the synthetic product have identical HPLC retention times, fluorescence spectra, fluorescence intensities as a function of pH value and electrochemical behaviour.
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 148776-250MG | 04061838738042 |
| 148776-1G | 04061826100523 |